General Information

We are a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We have a portfolio of clinical and preclinical compounds that we believe are best-in-class due to their unique mechanism of action and where human proof of concept has been established for the compound or the target. We are currently pursuing regulatory approval of three product candidates: CERC-301, CERC-501 and CERC-406. CERC-301 is currently in Phase 2 development as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder, or MDD, who are failing to achieve an adequate response to their current antidepressant treatment and are severely depressed.

Employees: 11
Founded: 2011
Contact Information
Address 400 E. Pratt Street, Suite 606, Baltimore, MD 21202, US
Phone Number (410) 522-8707
Web Address http://www.cerecor.com
View Prospectus: Cerecor
Financial Information
Market Cap $55.9mil
Revenues $0.0 mil (last 12 months)
Net Income $-1.98 mil (last 12 months)
IPO Profile
Symbol CERCU
Exchange NASDAQ
Shares (millions): 4.0
Price range $6.50 - $6.50
Est. $ Volume $26.0 mil
Manager / Joint Managers Maxim Group LLC
CO-Managers Laidlaw & Company (UK) Ltd.
Expected To Trade: 10/15/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change